EGFR and cancer: The importance of ADCC or CDC activity has been clinically demonstrated for obinutuzumab and rituximab, as well as other antibodies successful therapeutic IgG1 antibodies approved for the treatment of cancers, including alemtuzumab (CD52), trastuzumab (HER2), cetuximab (EGFR), and daratumumab (CD38) [48, 65].